Education
About Us
Working with TipRanks
Follow Us
Dr. Hoenle AG (DE:HNL)
XETRA:HNL
HNL Stock Chart & Stats
€7.10
-€0.20(-2.86%)
At close: 4:00 PM EST
€7.10
-€0.20(-2.86%)
Day’s Range― - ―
52-Week Range€6.48 - €11.90
Previous CloseN/A
Volume3.05K
Average Volume (3M)6.13K
Market Cap
€57.22M
Enterprise Value€98.31M
Total Cash (Recent Filing)€6.71M
Total Debt (Recent Filing)€47.80M
Price to Earnings (P/E)―
Beta0.73
Next Earnings
May 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.25
Shares Outstanding6,062,930
10 Day Avg. Volume3,193
30 Day Avg. Volume6,130
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)0.65
Price to Sales (P/S)0.53
P/FCF Ratio15.82
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.03
Revenue Forecast (FY)€100.27M
Bulls Say, Bears Say
Bulls Say
Cash GenerationPositive trailing‑12‑month operating cash flow (~€5.2m) and free cash flow (~€3.2m) provide internal funding for operations and selective investments. Sustained FCF reduces reliance on external financing, supports aftermarket product support, and cushions near‑term earnings volatility while management executes recovery.
Manageable LeverageDebt around 0.63x equity suggests the balance sheet is not overly stretched, giving the company financial flexibility to fund working capital and capex without acute refinancing stress. This improves resilience to cyclical downturns and supports medium‑term investments in product development and aftermarket capabilities.
Revenue Recovery TrendA TTM revenue uptick (+6.8%) and narrowing losses indicate the company is emerging from prior contraction. Stabilizing top‑line demand underpins recurring aftermarket sales (lamps, components, services) and offers potential operating leverage, which can sustainably improve margins if the growth trend persists.
Bears Say
Ongoing UnprofitabilityThe company still reports net losses and negative EBIT, showing earnings power has not been reestablished. Persistent unprofitability limits retained earnings, constrains reinvestment capacity, and means that operational improvements must be sustained to convert positive cash flow into durable profit margins.
Negative Return On EquityA TTM ROE near -4% indicates the business is currently destroying equity value rather than creating it. Continued negative ROE undermines investor confidence, hampers ability to raise equity on favorable terms, and signals that profitability must improve materially to justify reinvestment.
Historic Cash/margin VolatilityPrior episodes of negative operating and free cash flow demonstrate that cash generation and margins are cyclical and can reverse. This volatility raises execution and liquidity risk: weaker industrial capex or aftermarket demand could quickly erode recent gains and force financing or cost cuts.
Dr. Hoenle AG News
HNL FAQ
What was Dr. Hoenle AG’s price range in the past 12 months?
Dr. Hoenle AG lowest stock price was €6.48 and its highest was €11.90 in the past 12 months.
What is Dr. Hoenle AG’s market cap?
Dr. Hoenle AG’s market cap is €57.22M.
When is Dr. Hoenle AG’s upcoming earnings report date?
Dr. Hoenle AG’s upcoming earnings report date is May 13, 2026 which is in 59 days.
How were Dr. Hoenle AG’s earnings last quarter?
Dr. Hoenle AG released its earnings results on Feb 24, 2026. The company reported -€0.25 earnings per share for the quarter, missing the consensus estimate of -€0.218 by -€0.032.
Is Dr. Hoenle AG overvalued?
According to Wall Street analysts Dr. Hoenle AG’s price is currently Overvalued.
Does Dr. Hoenle AG pay dividends?
Dr. Hoenle AG pays a Annually dividend of €0.2 which represents an annual dividend yield of N/A. See more information on Dr. Hoenle AG dividends here
What is Dr. Hoenle AG’s EPS estimate?
Dr. Hoenle AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Dr. Hoenle AG have?
Dr. Hoenle AG has 6,062,930 shares outstanding.
What happened to Dr. Hoenle AG’s price movement after its last earnings report?
Dr. Hoenle AG reported an EPS of -€0.25 in its last earnings report, missing expectations of -€0.218. Following the earnings report the stock price went up 6.54%.
Which hedge fund is a major shareholder of Dr. Hoenle AG?
Currently, no hedge funds are holding shares in DE:HNL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dr. Hoenle AG Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.44%
12-Months-Change
Fundamentals
Return on Equity
-15.84%
Trailing 12-Months
Asset Growth
-11.57%
Trailing 12-Months
Company Description
Dr. Hoenle AG
Dr. Hönle AG supplies industrial UV technologies and systems in Germany and internationally. The company operates through three segments: Adhesives, Equipment & Systems, and Glass & Lamps. The Adhesives segment provides industrial adhesives for applications, such as consumer electronics, medical technology, optics and opto electronics, automotive, and glass processing. The Equipment & Systems segment engages in the drying of inks and coatings, curing of adhesives and plastics, disinfecting surfaces, and solar simulation. The Glass & Lamps segment offers quartz glass tubing and rods for the lamp, automotive, semiconductor, and fibre cable industries, as well as lamps for water disinfection, and the drying of coatings and adhesives. The company was founded in 1976 and is headquartered in Munich, Germany.
Technical Analysis
Options Prices
Currently, No data available
---